Review article · 2026 · Open access

Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations

Shigeru Iwata, Masahiro Tada, Ryuji Koike, Yuji Yamanishi, Mie Fusama, Haruka Tsuchiya, Kunihiro Yamaoka, Hideto Kameda

Modern Rheumatology, 36(6), 861–868 · Published 1 September 2026 · DOI 10.1093/mr/roag080

Open full textCite this paper

In brief

“Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations” is a 2026 review article by Shigeru Iwata and 7 co-authors, published in Modern Rheumatology. OpenAlex counts 0 citations as of 19 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Modern Rheumatology.

Citations
0
References
40
Authors
8

Abstract

In this review, we summarized the current evidence on the risks of incident malignancy and cancer recurrence in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX). Before considering the effect of MTX, it is important to recognize the malignancy risk associated with RA itself. The overall risk of malignancy in patients with RA modestly increased, as per two meta-analyses, although Japanese studies report inconsistent findings, with one showing a slight decrease and another a slight increase. The risk of malignant lymphoma is increased, whereas the risk of colorectal cancer appears to be reduced. Additionally, there are concerns regarding the increased risk of lung and skin cancers. However, there is limited evidence specific to patients with RA treated with MTX. According to an Australian report, these patients have a higher risk of overall malignancy, along with an increased risk of malignant lymphoma, lung cancer, and melanoma. Studies comparing MTX with tumour necrosis factor inhibitors have reported no significant difference in the overall malignancy risk or increased malignancy risk. In White patients, MTX has been associated with an increased risk of recurrence in patients with RA and a history of non-melanoma skin cancer. There is insufficient evidence regarding the risks of MTX use in patients with RA and malignancy. Therefore, decisions regarding MTX use should be made individually based on shared decision-making, and careful follow-up is necessary.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Iwata, S., Tada, M., Koike, R., Yamanishi, Y., Fusama, M., Tsuchiya, H., Yamaoka, K., & Kameda, H. (2026). Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations. Modern Rheumatology, 36(6), 861–868. https://doi.org/10.1093/mr/roag080

MLA 9

Iwata, Shigeru, et al. “Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations.” Modern Rheumatology, vol. 36, no. 6, 2026, pp. 861–868. https://doi.org/10.1093/mr/roag080.

Chicago

Iwata, Shigeru, Masahiro Tada, Ryuji Koike, Yuji Yamanishi, Mie Fusama, Haruka Tsuchiya, Kunihiro Yamaoka, and Hideto Kameda. 2026. “Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations.” Modern Rheumatology 36 (6): 861–868. https://doi.org/10.1093/mr/roag080.

Harvard

Iwata, S. et al. (2026) ‘Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations’, Modern Rheumatology, 36(6), pp. 861–868. doi:10.1093/mr/roag080.

IEEE

S. Iwata et al., “Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations,” Modern Rheumatology, vol. 36, no. 6, pp. 861–868, 2026, doi: 10.1093/mr/roag080.

BibTeX

@article{iwata2026methotrexate,
  title     = {{Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations}},
  author    = {Iwata, Shigeru and Tada, Masahiro and Koike, Ryuji and Yamanishi, Yuji and Fusama, Mie and Tsuchiya, Haruka and Yamaoka, Kunihiro and Kameda, Hideto},
  journal   = {Modern Rheumatology},
  year      = {2026},
  volume    = {36},
  number    = {6},
  pages     = {861--868},
  doi       = {10.1093/mr/roag080},
  url       = {https://doi.org/10.1093/mr/roag080}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • methotrexate
  • rheumatoid arthritis
  • cancer risk
  • tumor recurrence
  • lymphoma
  • lung cancer
  • melanoma
  • non-melanoma skin cancer

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Iwata, S., Tada, M., Koike, R., Yamanishi, Y., Fusama, M., Tsuchiya, H., Yamaoka, K., & Kameda, H. (2026). Methotrexate and malignancy in rheumatoid arthritis: Evidence, risks, and clinical considerations. Modern Rheumatology, 36(6), 861–868. https://doi.org/10.1093/mr/roag080

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Modern Rheumatology: sign in and open the full text from this page.

Who wrote this paper?

Shigeru Iwata, Masahiro Tada, Ryuji Koike, Yuji Yamanishi, Mie Fusama, Haruka Tsuchiya, Kunihiro Yamaoka, Hideto Kameda.

What is the DOI of this paper?

10.1093/mr/roag080, permanently at https://doi.org/10.1093/mr/roag080. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.